Geographic Atrophy Clinical Trials in Hagerstown, Maryland
8 recruitingHagerstown, Maryland
Showing 1–8 of 8 trials
Recruiting
Phase 2
A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
Geographic AtrophyMacular Degeneration
Janssen Research & Development, LLC274 enrolled104 locationsNCT06635148
Recruiting
Phase 3
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
Age related macular degeneration (AMD)Geographic Atrophy (GA)
Regeneron Pharmaceuticals975 enrolled216 locationsNCT06541704
Recruiting
A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy
Geographic AtrophyMacular Degeneration
Astellas Pharma Global Development, Inc.1,000 enrolled65 locationsNCT06779773
Recruiting
Phase 2
Phase 2 Study of ADX-038 in Participants With Geographic Atrophy
Geographic Atrophy secondary to Age Related Macular Degeneration
ADARx Pharmaceuticals, Inc.240 enrolled24 locationsNCT06990269
Recruiting
Phase 1Phase 2
A Safety and Efficacy Study of a One-time Intravitreal Injection of SAR446597 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
Geographic Atrophy
Sanofi104 enrolled17 locationsNCT07215234
Recruiting
Phase 2
A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio
Geographic Atrophy secondary to Age Related Macular Degeneration
Apellis Pharmaceuticals, Inc.240 enrolled43 locationsNCT07215390
Recruiting
Phase 1
A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity of RO7669330 in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
Geographic Atrophy
Hoffmann-La Roche132 enrolled16 locationsNCT06961370
Recruiting
Phase 2
A Phase 2 Efficacy and Safety Study of GAL-101, 2% Ophthalmic Solution in Non-foveal Geographic Atrophy Secondary to Non-neovascular AMD
Geographic Atrophy of the Macula
Galimedix Therapeutics Inc110 enrolled14 locationsNCT06659549